Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Reply to ‘Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting’

Prostate Cancer and Prostatic Diseases volume 21, pages 446–447 (2018)Cite this article

Subjects

Prostate Cancer and Prostatic Diseases online publication, 20 November 2017; https://doi.org/10.1038/s41391-017-0008-7.

Guidelines recommend consideration of reflex biomarkers, such as the free-to-total prostate specific antigen (PSA), the Prostate Health Index (phi), the 4Kscore, or PCA3 to help determine, which men with elevated PSA and/or suspicious digital rectal examination (DRE) need a prostate biopsy [1]. These tests have been validated in large-scale prospective studies [2, 3] and are widely used. However, few have reported on the use of these tests for decision-making in real-world clinical practice.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Carroll PR, Parsons JK, Andriole G, et al. NCCN clinical practice guidelines in oncology (NCCN guidelines): prostate cancer early detection, version 2. 2017. www.nccn.org.

  2. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185:1650–5.

    Article  CAS  Google Scholar 

  3. Parekh DJ, Punnen S, Sjoberg DD, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015;68:464–70.

    Article  Google Scholar 

  4. White J, Shenoy BV, Tutrone RF, et al. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Prostate Cancer Prostatic Dis. 2018;21:78–84.

    Article  Google Scholar 

Download references

Funding

This work was supported in part by funds from the Sidney Kimmel Center for Prostate and Urologic Cancers, a Specialized Programs of Research Excellence grant (P50-CA92629) from the National Cancer Institute to Dr. Howard Scher, and a National Institutes of Health/National Cancer Institute Cancer Center Support Grant (P30-CA008748) to Memorial Sloan Kettering Cancer Center, a grant from the National Cancer Institute as part of the Cancer Intervention and Surveillance Modeling Network (U01CA199338-02), and the David H. Koch prostate cancer research fund.

Author information

Authors and Affiliations

  1. Urology Service at the Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA

    Behfar Ehdaie & Sigrid Carlsson

  2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA

    Sigrid Carlsson

  3. Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

    Sigrid Carlsson

Authors
  1. Behfar Ehdaie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sigrid Carlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Behfar Ehdaie.

Ethics declarations

Conflict of interest

SC has received a lecture fee and travel support from Astellas unrelated to this letter. The sponsor had no role in the writing of this letter, in the analysis or interpretation of data, and in the decision to publish the letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ehdaie, B., Carlsson, S. Reply to ‘Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting’. Prostate Cancer Prostatic Dis 21, 446–447 (2018). https://doi.org/10.1038/s41391-018-0052-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-018-0052-y

This article is cited by

Search

Advanced search

Quick links